Breaking News Instant updates and real-time market news.

AEGR

Changed to NVLN

, AZN

AstraZeneca

$30.17

-0.17 (-0.56%)

04:55
08/07/17
08/07
04:55
08/07/17
04:55

American Association of Diabetes Educators hold annual meeting

Annual Meeting of AADE 2017 is being held in Indianapolis, Indiana on August 4-7.

AEGR

Changed to NVLN

AZN

AstraZeneca

$30.17

-0.17 (-0.56%)

BSX

Boston Scientific

$26.83

0.09 (0.34%)

CAJ

Canon

$35.09

-0.05 (-0.14%)

DXCM

Dexcom

$71.14

0.4 (0.57%)

DPS

Dr Pepper Snapple

$90.66

-0.2 (-0.22%)

PODD

Insulet

$53.65

3.56 (7.11%)

MNKD

MannKind

$1.22

0.04 (3.39%)

MDT

Medtronic

$83.68

0.39 (0.47%)

MRK

Merck

$63.10

-0.42 (-0.66%)

NVO

Novo Nordisk

$42.06

-0.43 (-1.01%)

PG

Procter & Gamble

$90.67

-0.19 (-0.21%)

REGN

Regeneron

$468.76

1.65 (0.35%)

Q

symbol changed to IQV

$90.42

-0.68 (-0.75%)

SNY

Sanofi

$48.08

0.4 (0.84%)

SLXP

Bought by VRX

RHHBY

Roche

$31.92

0.07 (0.22%)

  • 07

    Aug

  • 09

    Aug

  • 15

    Aug

  • 15

    Aug

  • 21

    Aug

  • 21

    Aug

  • 28

    Aug

  • 06

    Sep

  • 08

    Sep

  • 20

    Sep

  • 22

    Sep

  • 30

    Nov

AEGR Changed to NVLN

11/11/16
JPMS
11/11/16
INITIATION
JPMS
Neutral
Aegerion resumed with a Neutral at JPMorgan
JPMorgan analyst Jessica Fye resumed coverage of Aegerion Pharmaceuticals with a Neutral rating. The analyst views 2016 as a "show me" year for the company given the "continued substantial impact to the Juxtapid franchise from the PCSK9s."
AZN AstraZeneca
$30.17

-0.17 (-0.56%)

08/01/17
PART
08/01/17
UPGRADE
PART
Hold
AstraZeneca upgraded to Hold from Sell at Pareto
07/28/17
07/28/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Starbucks (SBUX) was downgraded to Neutral from Buy at Guggenheim and to Hold from Buy at Stifel. 2. Spirit Airlines (SAVE) was downgraded to Neutral from Buy at Buckingham and BofA/Merrill and to In-Line from Outperform at Imperial Capital. 3. Flowers Foods (FLO) downgraded to Hold from Buy at Jefferies with analyst Akshay Jagdale saying his positive thesis on bread industry pricing becoming more rational has not played out. 4. AstraZeneca (AZN) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Vincent Meunier saying shares look fairly valued as he removed MYSTIC from his models. 5. U.S. Steel (X) downgraded to Sell from Neutral at Citi with analyst Alexander Hacking saying he sees downside risk to U.S. flat rolled prices for the remainder of 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/28/17
LEER
07/28/17
NO CHANGE
Target $61
LEER
Outperform
Bristol-Myers price target lowered to $61 after Astra trial setback at Leerink
Leerink analyst Seamus Fernandez said Bristol-Myers (BMY) reported "solid" Q2 results, including encouraging growth for its key franchises, but he sees increased uncertainty following the failure of AstraZeneca's (AZN) MYSTIC trial, which has potential read through to Bristol's CheckMate-227 trial of its I/O combo of Opdivo + Yervoy. Fernandez lowered his price target on Bristol shares to $61 from $66, but "fully acknowledges" the range of differences in the trial designs. He keeps an Outperform rating on Bristol-Myers, citing prospects for monotherapy Opdivo approval in the second-line setting and success in first-line liver cancer.
07/28/17
RHCO
07/28/17
NO CHANGE
RHCO
Merck, AstraZeneca deal positive, says SunTrust
After Merck (MRK) paid $1.6B upfront for access to Astrazeneca's (AZN) PARP inhibitor, Lynparza and another drug, SunTrust analyst John Boris says that the deal "makes strategic/financial sense and validates the PARP inhibitor class." He adds that the companies are "ideally positioned" to leverage a combination of IO and PARP therapies. The analyst reiterates a $73 price target and a Buy rating on Merck.
BSX Boston Scientific
$26.83

0.09 (0.34%)

06/28/17
RBCM
06/28/17
NO CHANGE
RBCM
RBC sees competing bid for Spectranetics as unlikely
RBC Capital analyst Glenn Novarro believes a competing bid for Spectranetics (SPNC) is unlikely and that Philips' (PHG) offer "signals a high probability of an on-time approval." The analyst notes Boston Scientific (BSX) is already developing a drug-eluting stent and a drug-coated balloon for peripheral artery disease and that Abbott (ABT) is integrating St. Jude while also soon closing its buyout of Alere (ALR).
07/17/17
COWN
07/17/17
NO CHANGE
Target $31
COWN
Outperform
Boston Scientific set up favorably for Q2, says Cowen
Cowen analyst Joshua Jennings believes Boston Scientific can retain its position as one of the premier large cap Med-Tech growth stories and does not expect Q2 results to slow its momentum. He believes its top line growth performance will remain and said it is possible to see another positive guidance revision. Jennings reiterated his Outperform rating and $31 price target on Boston Scientific shares.
06/28/17
STFL
06/28/17
NO CHANGE
STFL
Boston Scientific Analyst Day 'impressive,' says Stifel
Stifel analyst Rick Wise says that Boston Scientific's Analyst Day was "impressive. " He says that the company's 2018-2020 goals are "at least in-line" with the consensus outlook, and he continues to be upbeat about the company's longer term outlook. Wise raised his price target on the shares to $32 from $30 and keeps a Buy rating.
06/28/17
MSCO
06/28/17
NO CHANGE
Target $30
MSCO
Overweight
Boston Scientific long-term outlook faster than expected, says Morgan Stanley
Morgan Stanley analyst David Lewis said Boston Scientific's analyst day increased his conviction the company is now a structurally faster grower than previously expected and offers a unique top to bottom profile. The analyst sees continued innovation, market share gains, and emerging market penetration and said the $2B Structural Heart and balance sheet optionality are not fully reflected in valuation. Lewis rates Boston Scientific an Overweight with a $30 price target.
CAJ Canon
$35.09

-0.05 (-0.14%)

03/06/17
JPMS
03/06/17
UPGRADE
JPMS
Overweight
Canon upgraded to Overweight from Neutral at JPMorgan
10/26/16
JPMS
10/26/16
DOWNGRADE
JPMS
Underweight
Canon downgraded to Underweight from Neutral at JPMorgan
11/25/16
LYON
11/25/16
UPGRADE
LYON
Outperform
Canon upgraded to Outperform from Underperform at CLSA
10/27/16
BOFA
10/27/16
DOWNGRADE
BOFA
Underperform
Canon downgraded to Underperform from Neutral at BofA/Merrill
DXCM Dexcom
$71.14

0.4 (0.57%)

07/13/17
ADAM
07/13/17
NO CHANGE
Target $90
ADAM
Buy
Dexcom loss of Bigfoot as partner will be viewed negatively, says Canaccord
Canaccord analyst Kyle Rose said it is "hard not to view today's news" of a partnership with Bigfoot Biomedical as a big win for Abbott (ABT) and a disappointing loss for incumbent partner Dexcom (DXCM). While the loss of Bigfoot is unlikely to fundamentally impact Dexcom over the near term, Rose thinks investors will view it negatively since this news eliminates a potentially key pump partner for Dexcom and give's Abbott's Libre strategy a "strong backing," he tells investors. The analyst has a Buy rating and $90 price target on Dexcom shares.
07/13/17
BTIG
07/13/17
NO CHANGE
BTIG
Buy
Abbott, Bigfoot deal a 'major validation' for both, says BTIG
BTIG analyst Sean Lavin sees Abbott's (ABT) deal to collaborate with Bigfoot Biomedical as a major validation of both Abbott's Libre technology and the platform of Bigfoot, which he views as a leader in the development of automated pancreases. For Dexcom (DXCM), this is a missed opportunity that could also be a sign that its grip on the CGM market may fade over time, but the company still has multiple shots with other pump systems and remains the market leader of standalone CGM, said Lavin. Insulet (PODD) is well underway in developing its Horizon AP platform and is unlikely to switch from Dexcom for its CGM, added Lavin, who keeps a Buy rating on Abbott and a Neutral rating on Dexcom.
08/02/17
SPHN
08/02/17
NO CHANGE
Target $83
SPHN
Overweight
Dexcom price target lowered to $83 from $95 at Stephens
Stephens analyst Chris Cooley lowered his price target for Dexcom to $83 from $95 after the company reported Q2 operating results. The analyst reiterates an Overweight rating on the shares.
08/02/17
OPCO
08/02/17
NO CHANGE
Target $92
OPCO
Outperform
Dexcom price target lowered to $92 from $98 at Oppenheimer
Oppenheimer analyst Steven Lichtman lowered his price target for Dexcom to $92 from $98 on reduced sales offset by recent peer multiple appreciation. The analyst reiterates an Outperform rating on the shares.
DPS Dr Pepper Snapple
$90.66

-0.2 (-0.22%)

05/16/17
05/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AIG (AIG) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Kai Pan citing the "strong" new Chief Executive Officer and attractive valuation. 2. Yum! Brands (YUM) upgraded to Buy from Hold at Argus with analyst John Staszak citing the company's decision to refranchise an additional 5% of its stores and institute additional cost cutting measures as reasons for the upgrade. 3. Dr Pepper Snapple (DPS) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Dara Mohsenian saying the company's organic sales growth is accelerating driven by an improved competitive outlook as Coca Cola (KO) and Pepsi (PEP) focus on using cash flow from the U.S. carbonated soft drink segment in high growth areas. 4. Regal Entertainment (RGC) upgraded to Buy from Hold at Loop Capital with analyst David Millerciting recent weakness in shares and has confidence the company will pay a special dividend to shareholders around the fourth quarter or in the first half of 2018. 5. Vipshop (VIPS) upgraded to Overweight from Neutral at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/07/17
06/07/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ormat Technologies (ORA) upgraded to Overweight from Neutral at JPMorgan with analyst Paul Coster saying he believes the company is well positioned to continue posting revenue growth and margin expansion over the next few years. 2. Tenet (THC) upgraded to Outperform from Market Perform at Leerink. 3. Cott Corp. (COT) and Dr Pepper Snapple (DPS) were upgraded to Outperform from Market Perform at BMO Capital. 4. Sun Life Financial (SLF) upgraded to Outperform from Sector Perform at RBC Capital with analyst Darko Mihelic saying net flows and Assets Under Management at the company's MFS unit have improved over the last two months. He also notes that the stock has fallen about 12% since February. 5. Valvoline (VVV) upgraded to Buy from Neutral at Seaport Global with analyst Michael Harrison saying he expects the oil market to return to looser supply/demand and pricing to decline in the summer once Motiva completes its Port Arthur, TX turnaround in June, which would be a positive for Valvoline margins. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/07/17
BMOC
06/07/17
UPGRADE
BMOC
Outperform
Dr Pepper Snapple upgraded on valuation, earnings outlook at BMO Capital
As noted earlier, BMO Capital upgraded Dr Pepper Snapple to Outperform from Market Perform. Analyst Amit Sharma upgraded the stock based on valuation and his belief that its "attractive earnings growth outlook" makes its stock more likely to rise than a number of its peers' shares. He thinks that concerns about the sales growth of its Bai unit should dissipate. Target $105.
06/07/17
BMOC
06/07/17
UPGRADE
BMOC
Outperform
Dr Pepper Snapple upgraded to Outperform from Market Perform at BMO Capital
PODD Insulet
$53.65

3.56 (7.11%)

07/17/17
BTIG
07/17/17
DOWNGRADE
BTIG
Neutral
Insulet downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded Insulet to Neutral saying shares are fairly valued following recent share strength.
07/11/17
ADAM
07/11/17
NO CHANGE
Target $50
ADAM
Hold
Insulet fundamental set-up best in years, says Canaccord
Canaccord analyst Kyle Rose said his survey following last month's ADA conference showed an increasing demand for insulin pumps as well as expectations that Insulet's Dash product will gain market share over the next 18 months. He believes the company is entering a period of product cycle growth, leaving him increasingly bullish. Rose maintained his Hold rating but raised his price target to $50 from $42 on Insulet shares.
08/04/17
COWN
08/04/17
NO CHANGE
Target $63
COWN
Outperform
Insulet price target raised to $63 from $52 at Cowen
Cowen analyst Doug Schenkel raised his price target on Insulet to $63 from $52 following solid Q2 results. The analyst raised his estimates to account for the company going direct in Europe while also raising his long-term gross margin target. Schenkel, who also continues to see upside to 2019 estimates, reiterated his Outperform rating on Insulet shares.
MNKD MannKind
$1.22

0.04 (3.39%)

05/11/17
PIPR
05/11/17
NO CHANGE
Target $0.54
PIPR
Underweight
MannKind sales of Afrezza remain slow, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says sales of MannKind's Afrezza "failed to meaningfully inflect" in Q1 despite new commercialization initiatives. The company continues to drain its cash, Schimmer tells investors in a post-earnings research note. He reiterates an Underweight rating on MannKind with a 54c price target.
08/09/16
PIPR
08/09/16
NO CHANGE
Target $0.1
PIPR
Underweight
MannKind cash strapped, Afrezza sales 'abysmal,' says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer reiterates an Underweight rating on shares of MannKind with a 10c price target following the company's Q2 results. "Cash strapped" MannKind will have a tough time inflecting "rather abysmal" Afrezza sales rapidly enough to offset its cash burn, Schimmer tells investors in a post-earnings research note.
MDT Medtronic
$83.68

0.39 (0.47%)

07/31/17
DBAB
07/31/17
NO CHANGE
Target $96
DBAB
Buy
Medtronic attractive following share underperformance, says Deutsche Bank
Deutsche Bank analyst Brittany Henderson believes Medtronic shares represent an attractive investment opportunity after underperforming the broader S&P 500 medical supplies and devices index over the last 12 months. The company is well positioned for the "changing dynamics of the global healthcare environment," Henderson tells investors in a research note tilted "It is Time to Appreciate the Margin Expansion Story; Buy." She views the company as a mid-single digit sales and double digit earnings grower. The analyst reiterates a Buy rating on Medtronic with a $96 price target.
06/20/17
ADAM
06/20/17
NO CHANGE
Target $10
ADAM
Buy
Novadaq competing bids possible if not probable, says Canaccord
Canaccord analyst Jason Mills noted Novadaq (NVDQ) received an acquisition offer from Stryker (SYK) at a much greater equity value than what the company was trading at prior to the bid. Although he thinks Stryker is the most logical buyer of the franchise, he thinks there are several other potential acquirers, including Medtronic (MDT), Johnson & Johnson (JNJ) and Intuitive Surgical (ISRG), in that order. Mills believes this is a good exit for the company and that Stryker is getting a good asset. Mills maintains his Buy rating and $10 price target on Novadaq shares.
07/06/17
WBLR
07/06/17
INITIATION
WBLR
Outperform
Medtronic initiated with an Outperform at William Blair
William Blair analyst Kaila Krum started Medtronic with an Outperform rating.
07/06/17
07/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Nike (NKE) initiated with an Outperform at Raymond James. 2. JPMorgan (JPM) initiated with a Neutral at Goldman Sachs. 3. At Home Group (HOME) initiated with a Buy at SunTrust. 4. Logitech (LOGI) initiated with a Buy at Citi. 5. Medtronic (MDT) initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MRK Merck
$63.10

-0.42 (-0.66%)

07/27/17
GSCO
07/27/17
NO CHANGE
GSCO
Merck could trade up $5 following AstraZeneca MYSTIC failure, says Goldman Sachs
Goldman analyst Jami Rubin expects Merck (MRK) to trade up approximately $5 based on sentiment following AstraZeneca's MYSTIC failure as it partially de-risks longer-term estimates for Keytruda. As a result, the analyst raised Merck's Keytruda sales estimates by $600M in 2018 and $1B in 2019 and beyond, increasing earnings estimates by 14c-20c, and raising his price target on shares to $74 from $70. Rubin cautions that long-term estimates could be at risk if other competitor trials are successful. The analyst rates Merck a Neutral.
07/27/17
FBCO
07/27/17
NO CHANGE
FBCO
Merck unlikely to buy PARP company after Astra deal, says Credit Suisse
Credit Suisse analyst Alethia Young believes Merck (MRK) is unlikely to acquire a PARP inhibitor company like Tesaro (TSRO) or Clovis (CLVS) after inking an immuno-oncology deal with AstraZeneca (AZN).
07/27/17
JANY
07/27/17
NO CHANGE
Target $107
JANY
Buy
PARP deals may make Clovis more attractive buyout candidate, says Janney
The partnerships announced today between AstraZeneca (AZN) and Merck (MRK) as well as Tesaro (TSRO) and Takeda highlight pharma's willingness to expand on PARP's, Janney analyst Debjit Chattopadhyay tells investors in a research note. Clovis' (CLVS) Rubraca is now the only unencumbered PARP and is "far cheaper" on a relative valuation basis than peer Tesaro, the analyst adds. He believes Clovis could now become a more compelling takeover candidate. Chattopadhyay has a Buy rating on the shares with a $107 price target. The stock in midday trading is up 7%, or $5.90, to $93.33.
NVO Novo Nordisk
$42.06

-0.43 (-1.01%)

07/17/17
PIPR
07/17/17
NO CHANGE
Target $102
PIPR
Overweight
Eli Lilly's launch in type 2 diabetes 'remarkable,' says Piper Jaffray
Piper Jaffray analyst Richard Purkiss is highlighting the "remarkable growth story" of Eli Lilly's (LLY) once-weekly GLP-1 agonist Trulicity for type 2 diabetes. At its current pace, Trulicity would become market leader in the GLP-1 space in the early part of next year, surpassing Novo Nordisk's (NVO) Victoza, Purkiss tells investors in a research note. He views Lilly's launch as "quite simply unique in the current climate." Lilly remains one of the analyst's top 2017 picks with an Overweight rating and $102 price target.
03/21/17
WEDB
03/21/17
INITIATION
WEDB
Outperform
Global Blood Therapeutics coverage assumed with an Outperform at Wedbush
Wedbush analyst Liana Moussatos says that Global Blood Therapeutics' (GBT) GBT440 drug can become the standard of care for sickle cell disease, and he thinks that the stock has not risen adequately following speculation that the company had been approached by Novo Nordisk(NVO) about a takeover. The analyst thinks that the company could be acquired for $73-$87 per share, versus its current price of around $37. Target $73.
04/07/17
HSBC
04/07/17
DOWNGRADE
HSBC
Reduce
Novo Nordisk downgraded to Reduce from Hold at HSBC
HSBC analyst Steve McGarry downgraded Novo Nordisk to Reduce to reflect lackluster news flow, valuation risk, and a sector backdrop where US pricing pressure could intensify.
04/07/17
04/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Lamb Weston (LW) downgraded to Hold from Buy at Stifel with analyst Christopher Growe citing the 44% up move in shares since he launched coverage in November 2016. 2. AstraZeneca (AZN), Novo Nordisk (NVO), Sanofi (SNY), Roche (RHHBY), and Grifols (GRFS) were downgraded to Reduce from Hold at HSBC. 3. AECOM (ACM) downgraded to Neutral from Outperform at Baird with analyst Andrew Wittmann saying the company filed an amendment to its credit agreement suggesting likely risk to 2017 earnings, as the filing implies the company would have breached its leverage covenant without an amendment. The analyst is also cautious given the relative obscurity of the filing. Wittmann lowered his price target to $40 from $45 on AECOM shares. 4. Arista Networks (ANET) downgraded to Neutral on valuation at Nomura with analyst Jeffrey Kvaal citing valuation. 5. Maximus (MMS) downgraded to Hold from Buy at Canaccord analyst Richard Close citing expectations of a slow near-term RFP and contract award environment given the recent Trump administration transition. click here.
PG Procter & Gamble
$90.67

-0.19 (-0.21%)

07/17/17
DBAB
07/17/17
NO CHANGE
Target $90
DBAB
Hold
Procter & Gamble unlikely to miss near-term expectations, says Deutsche Bank
Deutsche Bank analyst Faiza Alwy believes Procter & Gamble's decision to not give Trian's Nelson Peltz a board seat as a sign that management is confident in its strategy and is unlikely to miss expectations over at least the next few months. The analyst notes the Wall Street Journal's reporting indicates that contrary to speculation from analysts, Trian is not seeking a breakup of the company. This idea was a non-starter given substantial dis-synergies and tax leakage, Alwy tells investors in a research note. The analyst keeps a Hold rating on the shares with a $90 price target.
03/21/17
JPMS
03/21/17
INITIATION
Target $98
JPMS
Neutral
Procter & Gamble initiated with a Neutral at JPMorgan
JPMorgan analyst Andrea Teixeira started Procter & Gamble with a Neutral rating and $98 price target.
03/06/17
03/06/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. MetLife (MET) downgraded to Neutral from Buy at BofA/Merrill with analyst Seth Weiss saying shares are now trading above the level of the disappointing fourth quarter earnings report and prefers Prudential (PRU) given it benefits more from improving interest rates and easing regulations. 2. Procter & Gamble (PG) downgraded to Neutral from Buy at B. Riley with analyst Linda Bolton Weiser saying that while the stock is up 11% from the December low, the company's fundamentals have weakened. The analyst cut her price target for the shares to $91 from $106. 3. GoPro (GPRO) downgraded to Sell from Neutral at Goldman with analyst Simona Jankowski saying the company faces "significant challenges" amid camera market saturation, product rollout issues in the holiday season, and a disappointing entry into the drone market. The analyst sees risk to consensus estimates and views the stock as overvalued. 4. Hawaiian Electric (HE) downgraded to Underperform from In Line at Evercore ISI with analyst Greg Gordon saying he believes the risk/return for shares is skewed to the downside and estimates a "significantly lower total return" compared to other utilities he covers. He maintains a $31 price target on Hawaiian Electric shares. 5. Akorn (AKRX) downgraded to Hold from Buy at Deutsche Bank with analyst Gregg Gilbert saying the risk/reward is more balanced following the recent rally in the shares. Upside from current levels will have more to do with the "hard-to-call dynamics of new product approvals vs. base business erosion," Gilbert tells investors in a research note. He cut his price target for the shares to $24 from $28. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/04/17
SUSQ
05/04/17
NO CHANGE
Target $41
SUSQ
Positive
Trade Desk wins Procter & Gamble as a customer, says Susquehanna
As reported by AdvertisingAge today, Procter & Gamble (PG) is moving its DSP business to Trade Desk's (TTD) platform in North America, as well as other geographies. Susquehanna analyst Shyam Patil said the win broadens Trade Desk's base of Tier 1 advertising partners and validates the company's market leadership and its ability to rapidly gain programmatic share. The analyst rates Trade Desk a Positive with a $41 price target.
REGN Regeneron
$468.76

1.65 (0.35%)

08/01/17
08/01/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. MGM Resorts (MGM) downgraded to Neutral from Buy at UBS with analyst Robin Farley saying the current valuation, with the shares up 37% over the past 12 months, now captures much of the value of the REIT transaction and improving Las Vegas outlook. 2. Boardwalk Pipeline (BWP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Elvira Scotto saying she expects the stock to be "range bound" until its 2019-2020 outlook become clearer. 3. La-Z-Boy (LZB) downgraded to Neutral from Buy at Sidoti with analyst Anthony Lebiedzinski saying shares are approaching his $36 price target. 4. Regeneron (REGN) downgraded to Underperform from Neutral at Baird with analyst Brian Skorney saying Dupixent expectations have gotten ahead of themselves and consensus numbers currently reflect an overlap with Cosentyx sales which looks like an overestimate. 5. Corporate Office Properties (OFC) downgraded to Sell from Hold at Stifel with analyst John Guinee saying he believes that the Real Estate Investment Trust will be hurt by "persistently weak leasing economics," the expirations of a large number of its leases with high rents, and efforts by defense and IT organization to keep rent costs low. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/04/17
SBSH
08/04/17
NO CHANGE
Target $575
SBSH
Buy
Regeneron price target raised to $575 from $555 at Citi
Citi analyst Robyn Karnauskas raised her price target for Regeneron Pharmaceuticals to $575 saying the company posted a beat and raise quarter with Eylea U.S. sales at $919M versus the $878M consensus. She views concerns over the Dupixent launch as overdone and keeps a Buy rating on Regeneron.
08/04/17
UBSW
08/04/17
NO CHANGE
Target $535
UBSW
Buy
Regeneron price target raised to $535 from $489 at UBS
UBS analyst Carter Gould raised his price target on Regeneron to $535 from $489, saying his channel checks suggest the continuation of the current pace of new starts for Dupixent, which should drive consensus sales. He sees the stock continuing to work as the next wave of pipeline assets move through clinical trials. Gould reiterated his Buy rating on Regeneron shares following its pullback since mid-June.
08/01/17
BARD
08/01/17
DOWNGRADE
Target $408
BARD
Underperform
Regeneron downgraded to Underperform at Baird
As previously reported, Baird analyst Brian Skorney downgraded Regeneron to Underperform from Neutral. He believes Dupixent expectations have gotten ahead of themselves and consensus numbers currently reflect an overlap with Cosentyx sales which looks like an overestimate. Skorney believes a greater degree of optimism is unwarranted. Skorney maintained his $408 price target on Regeneron shares.
Q symbol changed to IQV
$90.42

-0.68 (-0.75%)

06/21/17
WELS
06/21/17
NO CHANGE
WELS
QuintilesIMS added to Priority Stock List at Wells Fargo
Wells Fargo added QuintilesIMS (Q) to its Priority Stock List and removed ICON plc (ICLR). The firm thinks that QuintilesIMS' EPS can reach about $7 per share in 2020, driven partly by capital deployment and cost synergies. It predicts that the stock's annualized return will come in at 14% over three years. After The Wall Street Journal reported that ICON was bidding for Parexel (PRXL), Wells Fargo is unhappy with the news, saying that the deal would potentially create revenue dis-synergies and that ICON's interest indicates that it might be threatened by rising competition. Wells keeps Outperform ratings on QuintilesIM and ICON.
05/03/17
WELS
05/03/17
DOWNGRADE
WELS
Market Perform
Medpace downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Tim Evans downgraded Medpace (MEDP) to Market Perform saying the company has "considerably lower visibility than peers" on 2017 and 2018. The analyst prefers contract research organizations that are most likely to be share takers in an increasingly competitive environment. He lowered his price target range for the shares to $23-$25 from $32-$33. Evans this morning also downgraded INC Research (INCR) to Market Perform. He views PRA Health (PRAH), ICON plc (ICLR) and QuintilesIMS (Q) as share takers in the CRO space.
08/04/17
WBLR
08/04/17
UPGRADE
WBLR
Outperform
QuintilesIMS upgraded to Outperform from Market Perform at William Blair
William Blair analyst John Kreger upgraded QuintilesIMS to Outperform following the company's Q2 results. The analyst sees an improved valuation relative to peers and believes macro demand for clinical contract research organizations is improving.
06/12/17
KEYB
06/12/17
NO CHANGE
KEYB
CROs should benefit from growth of risk-based monitoring, says KeyBanc
KeyBanc says that industry guidelines recently adopted by the EU should be a catalyst for risk-based monitoring technologies, or RBM. KeyBanc says that CROs such as QuintilesIMS (Q) and ICON plc (ICON) can bundle their risk-based monitoring software-as-a-service with their other services, generating efficiencies which can increase their profits. The analyst adds that the increased use of RBM should increase the CROs' gross margins and market share over the longer run. The firm raised its price target on QuintilesIMS to $96 from $90 and on ICON to $103 from $98. It keeps Overweight ratings on QuintilesIMS and ICON.
SNY Sanofi
$48.08

0.4 (0.84%)

07/10/17
PIPR
07/10/17
NO CHANGE
Target $126
PIPR
Overweight
Alnylam shares overreacting to ALT elevations in OLE data, says Piper Jaffray
Alnylam (ALNY) and partner Sanofi (SNY) presented new Phase II open-label extension study data on 33 hemophilia patients being treated with fitusiran and reported that eleven patients reported asymptomatic ALT increases, up from three observed in its ASH meeting update, noted Piper Jaffray analyst Edward Tenthoff. However, he thinks the stock is overreacting, as the liver enzyme elevations were asymptomatic and largely reversed within one month, he tells investors. Tenthoff, who also sees the efficacy data as encouraging, reiterates his Overweight rating and $126 price target on Alnylam shares.
07/31/17
ADAM
07/31/17
NO CHANGE
Target $522
ADAM
Buy
Dupixent authorization approval rate outweighs Q2 miss, says Canaccord
Regeneron (REGN) partner Sanofi (SNY) reported a "very high" 73%-83% prior authorization approval rate for Dupixent in Q2, which Canaccord analyst John Newman said outweighs the fact that sales for the drug at $30.6M were slightly below the $33M consensus forecast. The analyst, who sees rapid payor acceptance of Dupixent as "much more crucial" than the initial quarterly revenue, keeps a Buy rating and $522 price target on Regeneron shares.
07/31/17
PIPR
07/31/17
NO CHANGE
Target $557
PIPR
Overweight
Regeneron indicated lower after Sanofi earnings report, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says shares of Regeneron (REGN) are indicated lower after partner Sanofi (SNY) reported Q2 U.S. Dupixent sales of $30M in adults with atopic dermatitis. This was essentially in line with the consensus estimate of $33M, Tenthoff tells investors in a research note. He adds that over 5,100 physicians have prescribed and over 13,000 atopic dermatitis patients have been prescribed Dupixent as of July 26. The analyst views the launch stats as impressive and reiterates an Overweight rating on Regeneron with a $557 price target.
07/14/17
WELS
07/14/17
NO CHANGE
Target $41
WELS
Outperform
Wells says smallpox vaccine deal an 'excellent fit' for Emergent BioSolutions
Wells Fargo analyst David Maris said Emergent BioSolutions' (EBS) deal to acquire the ACAM2000 smallpox vaccine business of Sanofi (SNY) is "an excellent fit" and he is "encouraged" by its ability to identify and make a deal for such a "solid target." Maris keeps an Outperform rating and $41 price target on Emergent BioSolutions.
SLXP Bought by VRX

RHHBY Roche
$31.92

0.07 (0.22%)

07/06/17
UBSW
07/06/17
DOWNGRADE
UBSW
Neutral
Roche downgraded to Neutral from Buy at UBS
UBS analyst Jack Scannell downgraded Roche to Neutral saying he's become more cautious on oncology in general and that the shares are close to his fair value estimate. The analyst has a CHF 260 price target for the shares.
07/11/17
FBCO
07/11/17
NO CHANGE
Target $96
FBCO
Outperform
Alnylam weakness more driven by competitor data, says Credit Suisse
While attending the ISTH meeting in Berlin, Credit Suisse analyst Alethia Young notes that Alnylam's (ALNY) stock weakness is more driven by "strong" competitor data in inhibitors from Roche's (RHHBY) ACE910. The analyst reiterates an Outperform rating and $96 price target on Alnylam's shares.
07/14/17
CANT
07/14/17
NO CHANGE
CANT
Worries about Shire hemophilia franchise overdone, says Cantor
After speaking with a pediatric hematology/oncology physician, Cantor analyst Louise Chen reports that the doctor said that uptake of Roche's (RHHBY) hemophilia treatment, ACE910, "will be gradual" because of safety concerns. The analyst says that worries about Shire's (SHPG_) hemophilia franchise are overdone. She keeps a $222 price target and an Overweight rating on the stock.
07/11/17
COWN
07/11/17
NO CHANGE
Target $325
COWN
Outperform
Shire hemophilia franchise being valued near zero, says Cowen
Cowen analyst Ken Cacciatore believes Shire's (SHPG) current valuation reflects essentially no value for the company's hemophilia franchise. Investors are treating Shire/Baxalta's hemophilia franchise as if it should equate to essentially zero, into perpetuity, beginning in 2020, Cacciatore tells investors in a research note, citing his analysis. He believes this sentiment, based on competitive concerns from Roche (RHHBY) and Alnylam (ALNY), is a "gross overreaction." The analyst has an Outperform rating on Shire with a $325 price target.

TODAY'S FREE FLY STORIES

03:05
01/22/18
01/22
03:05
01/22/18
03:05
General news
FX Update: The dollar dipped at the open of Asia-Pacific dealings »

FX Update: The dollar…

02:55
01/22/18
01/22
02:55
01/22/18
02:55
Conference/Events
Morgan Stanley transportation analysts hold an analyst/industry conference call »

ASEAN Transportation VP…

FCX

Freeport McMoRan

$19.96

0.56 (2.89%)

21:10
01/21/18
01/21
21:10
01/21/18
21:10
Downgrade
Freeport McMoRan rating change at CIBC »

Freeport McMoRan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

DCM

NTT DoCoMo

$24.74

0.08 (0.32%)

21:09
01/21/18
01/21
21:09
01/21/18
21:09
Downgrade
NTT DoCoMo rating change at HSBC »

NTT DoCoMo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$53.01

0.65 (1.24%)

, PETS

PetMed Express

$53.24

2.67 (5.28%)

20:25
01/21/18
01/21
20:25
01/21/18
20:25
Earnings
Notable companies reporting before Monday's open »

Notable companies…

HAL

Halliburton

$53.01

0.65 (1.24%)

PETS

PetMed Express

$53.24

2.67 (5.28%)

OPB

Opus Bank

$28.70

0.05 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

20:00
01/21/18
01/21
20:00
01/21/18
20:00
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

SNE

Sony

$49.89

0.72 (1.46%)

BA

Boeing

$337.73

-2.43 (-0.71%)

WMT

Walmart

$104.59

0.29 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 07

    Feb

  • 20

    Feb

  • 21

    Feb

  • 28

    Feb

  • 18

    Mar

XRX

Xerox

$31.80

0.43 (1.37%)

19:18
01/21/18
01/21
19:18
01/21/18
19:18
Periodicals
Icahn, Deason pushing for Xerox to explored sale, WSJ reports »

Carl Icahn and Darwin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

18:22
01/21/18
01/21
18:22
01/21/18
18:22
Periodicals
Facebook to open three new digital training hubs in Europe, Reuters says »

Facebook said it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 28

    Feb

TWX

Time Warner

$93.36

0.39 (0.42%)

, CMCSA

Comcast

$42.50

0.65 (1.55%)

17:56
01/21/18
01/21
17:56
01/21/18
17:56
Hot Stocks
Box Office Battle: 'Jumanji' wins weekend with $20M »

Once again, Sony's…

TWX

Time Warner

$93.36

0.39 (0.42%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

SNE

Sony

$49.89

0.72 (1.46%)

FOX

21st Century Fox

$36.26

0.53 (1.48%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

LGF.A

Lionsgate

$35.42

0.92 (2.67%)

DIS

Disney

$110.59

0.17 (0.15%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

CTIC

CTI BioPharma

16:11
01/21/18
01/21
16:11
01/21/18
16:11
Conference/Events
CTI BioPharma to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ZSAN

Zosano Pharma

$0.45

-0.0387 (-7.92%)

16:00
01/21/18
01/21
16:00
01/21/18
16:00
Conference/Events
Zosano Pharma to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SANM

Sanmina

$35.45

0.5 (1.43%)

15:39
01/21/18
01/21
15:39
01/21/18
15:39
Conference/Events
Sanmina to hold a conference call »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

12:05
01/21/18
01/21
12:05
01/21/18
12:05
Periodicals
Amazon automated grocery store opens Monday, Reuters says »

Amazon will open its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 18

    Mar

TWTR

Twitter

$23.66

-0.38 (-1.58%)

09:07
01/21/18
01/21
09:07
01/21/18
09:07
Periodicals
Twitter COO in discussions to become SoFi CEO, WSJ reports »

Twitter's COO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

CLF

Cleveland-Cliffs

$8.49

0.08 (0.95%)

09:02
01/21/18
01/21
09:02
01/21/18
09:02
Hot Stocks
Cleveland-Cliffs addresses ''inaccurate media reports' on Nashwauk property »

Cleveland-Cliffs said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

15:26
01/20/18
01/20
15:26
01/20/18
15:26
Hot Stocks
Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22
Hot Stocks
Exelixis presents updated results from Phase 1b clinical trial in CRC »

Exelixis (EXEL) announced…

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

15:17
01/20/18
01/20
15:17
01/20/18
15:17
Hot Stocks
Array BioPharma updates results from BEACON Phase 3 trial »

Array BioPharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 30

    Jun

SO

Southern Company

$44.44

-0.46 (-1.02%)

15:13
01/20/18
01/20
15:13
01/20/18
15:13
Hot Stocks
Southern Company accelerates restoration efforts in Puerto Rico »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.43

0.19 (0.65%)

15:10
01/20/18
01/20
15:10
01/20/18
15:10
Hot Stocks
Teck Resources announces Elkview incident »

Teck Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.